INTRODUCTION
Inflammatory bowel diseases (IBD) are chronic, relapsing and remitting diseases that are characterised by inflammation of the gastrointestinal tract. 1 They are disabling disorders that occur mostly in young patients and that are associated with a decrease in quality of life. Early diagnosis and timely introduction of therapy is important to achieve better long-term outcomes. Aminosalicylates, corticosteroids, and immunomodulators (e.g. azathioprine, mercaptopurine and methotrexate) have been used traditionally to control symptoms. With the advent of biological therapies, the aim of treatment has transformed tremendously. Indeed, biological agents have shown to be able to alter the natural course of the disease. 2 Adalimumab, a subcutaneous fully human antitumour necrosis factor monoclonal antibody (anti-TNF), has shown to induce and maintain clinical remission in patients with moderate-to-severe Crohn's disease (CD) and ulcerative colitis (UC). [3] [4] [5] [6] [7] [8] Furthermore, adalimumab therapy is also able to induce mucosal healing in both conditions, 7, 9 and it has been associated with lower hospitalisation and surgery rates, as well as an increased quality of life. [10] [11] [12] The conventional adalimumab induction scheme is 160 mg at week zero, and 80 mg at week two, followed by a maintenance therapy with adalimumab 40 mg every other week. 3, 7 With the introduction of therapeutic drug monitoring, the provision of personalised medicine has become available. 13 Therapeutic drug monitoring may improve clinical outcome by individualising therapy. 14 Tight drug monitoring has frequently been proposed to guide dose escalation, 15, 16 but less is known about the possibilities of de-escalation of therapy. Indeed, dose de-escalation might also have an important impact, not only by reducing health care costs, but possibly also by decreasing adverse events linked to biological therapy. Cutaneous reactions are among the most common adverse events, with an estimated prevalence of 1.6-22%. 17, 18 Paradoxical anti-TNF-induced psoriasiform and eczematiform skin lesions are one of the most frequent cutaneous side effects observed, but other (immune-mediated) diseases, such as infections, lupus, vasculitis and rarely skin cancers can also occur. They can lead to treatment cessation in 21-34% of the patients treated with anti-TNF for rheumatological diseases or IBD. 19 Also paradoxical arthralgias and arthritis have been observed. Data regarding the use of therapeutic drug monitoring in the (dis)appearance of adverse events are limited.
Therapeutic drug monitoring is also a promising way to identify candidates for dose de-escalation. For patients with IBD, as for rheumatoid arthritis and ankylosing spondylitis, little is known about the optimal serum levels and optimal duration of therapy with biologicals once remission is achieved. The TAXIT study showed that patients with an infliximab (IFX) trough level of >7 lg/mL could be safely dose de-escalated without losing response.
14 The ideal serum level for adalimumab is still not clear, but is probably situated somewhere between 4 and 10 lg/mL.
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Although dose de-escalation has been shown possible in patients with CD who previously had to escalate to adalimumab 40 mg every week, 24 there are no clinical data available on further down-titration of adalimumab therapy to 40 mg every 3 weeks. Therefore, we studied the outcome of dose de-escalation to adalimumab 40 mg every 3 weeks in patients with CD. Furthermore, we tried to identify predictors of mid-term outcome after dose de-escalation, and we evaluated the effect on adalimumab-related adverse events.
MATERIALS AND METHODS

Patient population
For this retrospective cohort study we reviewed clinical data from all 898 patients who had received adalimumab for CD or UC before July 2015 at the University Hospitals Leuven, Belgium. We selected those patients who were switched from a therapy of adalimumab every other week to every 3 weeks and from whom serum levels were available both before and after dose de-escalation. Patients who had temporarily postponed adalimumab administration due to an infection or decreased compliance were not included. Since we identified only four patients with UC fulfilling all inclusion criteria, we decided to limit the study population to patients with CD.
For the control population, we selected age-and sexmatched patients with CD who continued adalimumab every other week with adequate adalimumab serum levels (above 7 lg/mL). Next, we made a random list of all 323 patients under adalimumab every other week and a serum level of at least 7 lg/mL, and looked top-down for a patient with the same sex, and the same age (AE1 year difference). In case more than one option was possible, we chose the patient with presence of adalimumab-related adverse events. In case no match was found, the age criterion (AE2 or 3 years difference) was simplified.
A detailed retrospective review was performed to look for baseline variables, including disease location and disease behaviour (according to the Montreal classification), 25 age at diagnosis, disease duration, familial IBD, smoking behaviour, prior and concomitant medication, body mass index (BMI), C-reactive protein (CRP) and serum albumin level. The reasons which led to dose deescalation were identified and categorised as skin manifestation, arthralgia, recurrent infections, injection site reaction and other. In addition, patient reported outcome (PRO2) was extracted retrospectively from the available data in the clinical charts. 26, 27 Patient records were checked until last visit. Written informed consent was provided by all patients in the framework of the Institutional Review Boardapproved Flemish Inheritance study for Crohn's and colitis (VLECC; B322201213950/S53684).
Serum levels of adalimumab and study time-points In our institute, serum is collected prospectively at each out-patient clinic in the majority of patients under biological therapy. Per protocol, serum was available in all patients both at dose de-escalation (T0) and approximately 4 months after dose de-escalation (T1). In 31 of these patients serum was also available approximately 4 months prior to dose de-escalation (T-1), while in 25 out of 40 patients serum was also available approximately 8 months after dose de-escalation (T2). Patients who had initiated adalimumab only 3 months prior to dose de-escalation were excluded for this study because of the higher serum levels during and shortly after induction therapy. Adalimumab serum levels were measured using RIDASCREEN monitoring kit (R-Biopharm AG, Darmstadt, Germany) which is principally based on an in-house developed, clinically validated, TNF-coated enzyme-linked immunosorbent assay. 28 At each of the time-points (T-1, T0, T1, T2) data were collected on CRP and serum albumin, as well as PRO2.
Definitions
The primary outcome was the need for dose escalation back to adalimumab 40 mg every other week after dose de-escalation to adalimumab 40 mg every 3 weeks. Dose escalation could be triggered by clinical relapse, low adalimumab serum levels (<4 lg/mL), or both. The cut-off of 4 lg/mL for a suboptimal adalimumab serum level was pre-specified based on the available literature. [20] [21] [22] [23] A clinical relapse was defined as recurrent IBD symptoms requiring adalimumab dose escalation, adalimumab discontinuation, or addition of immunosuppressive therapy.
Dose discontinuation was defined as cessation of adalimumab therapy for any reason (clinical relapse, adverse events, or other). Disease remission was evaluated using the PRO2 and was defined as a mean daily stool frequency of ≤1.5, and a mean abdominal pain score of ≤1.
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Statistics
All statistical analyses were performed using the IBM SPSS 23.0 software. Mann-Whitney U, Wilcoxon Signed Rank test, and Cox regression were performed. Kaplan-Meier survival analysis was used to describe time to event analyses. To allow proper evaluation in a Kaplan-Meier survival analysis continuous variables such as body weight and CRP were recoded into a binary variable using quartile analysis. Univariate and multivariate analyses were performed to look for factors predicting success of dose de-escalation, clinical relapse, and relapse-related adalimumab discontinuation. A P-value less than 0.05 was considered significant. For multivariate analysis, factors significantly associated with the three endpoints of interest in univariate analysis (LogRank P < 0.05) were included in the Cox regression analysis.
RESULTS
Patient disposition and patient characteristics
Out of the 898 patients who had received at least one prescription of adalimumab, 47 patients ever received maintenance therapy with adalimumab every 3 weeks of whom 44 with use of therapeutic drug monitoring (adalimumab serum levels available at T0 and T1). Two other patients decided to expand the interval without consulting their gastroenterologist, and in another patient serum levels were missing ( Figure 1 ). Of the remaining 44 patients only four had UC and these were excluded from further analysis. So, we identified 40 patients with CD [11 male, median (interquartile range, IQR) age at dose de-escalation 37.1 (30.2-49.3) years] fulfilling all selection criteria. All 40 patients received monotherapy with adalimumab every other week, which was initiated at a median (IQR) of 43.0 (11.7-71.9) months prior to dose de-escalation. At baseline, serum was available a median (IQR) of 13 (9) (10) (11) (12) (13) (14) days after last adalimumab administration. Reasons for dose de-escalation were adalimumab-related adverse events (n = 1), adalimumab serum levels above 7 lg/mL (n = 8), or a combination of both (n = 31). The most frequent adverse events in the study group were skin manifestations (50%), arthralgia (19%) and frequent infectious symptoms (22%). Other reasons were injection site reactions (n = 1), human papilloma virus related lesions of the cervix (n = 1), and frequent headache (n = 2). More details are enlisted in Table S1 . Median PRO2 at dose deescalation was 0, and median CRP level 1.4 mg/L. All other patients' characteristics are listed in Tables 1 and 2 .
As highlighted in Table 1 , the control population consisted of another 40 patients with CD [11 male, median (IQR) age 36.2 (31.1-49.4) years] under adalimumab for a median (IQR) of 17.9 (5.2-54.9) months. As expected, patients in the control population had significantly lower median adalimumab serum levels at T0 [9.6 (8.1-11.1) vs. 12.0 (9.4-14.4) lg/mL, P = 0.002], and less frequently encountered adalimumab-related adverse events (58% vs. 80%, P = 0.030). The three types of adverse events which were recorded in the control group were skin manifestations (48%), arthralgia (39%) and frequent infectious symptoms (22%). None of the other evaluated variables were significantly different between the study population and control group (Tables 1 and 2 ).
Evolution of clinical and biochemical markers of disease activity after dose de-escalation After dose de-escalation, adalimumab serum levels dropped significantly (Table 2 and Table S2 ). The median (IQR) adalimumab serum level decreased from 12.0 (9.4-14.4) lg/mL at T0 to 7.9 (5.8-10.7) lg/mL at T1 (P < 0.001). This decrease was not associated with a change in median CRP or serum albumin levels, but a significant increase in PRO2 was observed [from 0.0 (0.0-6.0) to 2.0 (0.0-8.5), P = 0.027]. Evolution of adalimumab serum levels, body weight, CRP, serum albumin, and PRO2 between T-1 and T2 are demonstrated in Table S2 .
In the control group with CD patients continuing adalimumab every other week, serum levels remained stable, but we did observe a significant increase in CRP and PRO2 between T0 and T1 ( Table 2 ). Compared to the study population, the median drop in adalimumab serum levels between T0 and T1 was significantly higher in patients undergoing treatment de-escalation [3.65 (1.43-5.23) vs. À0.19 (À1.48-1.15), P < 0.001]. However, changes in clinical and biochemical parameters were similar between both groups.
Mid-term outcome
Clinical relapse free survival. During a median (IQR) follow-up of 23.8 (14.0-36.7) months after dose de-escalation, 12 patients (30%) patients developed a clinical relapse after a median (IQR) of 6.9 (2.8-14.5) months ( Figure 2 ). As shown in Table 3 , the only factor associated with clinical relapse free survival after adalimumab de-escalation in multivariate analysis, was a CRP less than 3.5 mg/L at baseline [odds ratio 4.21 (95% confidence interval, 95% CI 1.28-13.89), P = 0.018]. Data on univariate analysis are available in Table S3 .
During a median (IQR) follow-up of 46.2 (24.7-61.7) months, clinical relapse occurred in 6 out of 40 control patients, which was significantly lower than in the study population (15% vs. 30%, LogRank P = 0.027, Figure 2) . Dose escalation-free survival. During follow-up, 14/40 (35%) of study patients needed dose escalation back to adalimumab 40 mg every other week. The majority were due to clinical relapse (8/40), two patients because of too low serum levels alone (<4 lg/mL), and four patients because of both (Figure 3a) .
Factors that were associated with dose escalation-free survival after adalimumab de-escalation in univariate analysis were a body weight at T0 above 52 kg (LogRank P = 0.015) and a CRP <3.5 mg/L at T0 (LogRank P = 0.001) (Figure 3b,c) . Of note, the adalimumab serum levels at T0 were not predictive of dose escalation-free survival, nor was the adalimumab serum level at T1. In multivariate analysis, a CRP <3.5 mg/L at T0 was an independent predictor of dose escalation-free survival after adalimumab de-escalation [odds ratio 6.28 (95% CI 1.83-21.59), P = 0.004, Table 3] .
As expected fewer patients in the control group needed dose escalation throughout follow-up (3% vs. 35%, LogRank P < 0.001, Figure 3a) .
Relapse-related discontinuation free survival. During follow-up, 5/40 (12%) of the patients stopped adalimumab for loss of response after a median (IQR) of 17.0 (11.9-26.0) months ( Figure S1 ). Furthermore, 6/40 (15%) patients stopped adalimumab for (persisting) adverse events. The only factor associated with relapserelated discontinuation free survival was a CRP <3.5 mg/ L at dose de-escalation [odds ratio 12.70 (95% CI 1.37-117.62), P = 0.025, Table 3 ).
The need for adalimumab discontinuation was similar in the study and the control group, both for loss of response (12% vs. 15%, LogRank P = 0.713, Figure S1 ) as for adverse events (15% vs. 27%, LogRank P = 0.696).
Disappearance of adverse events
In 53% of the 32 patients, adalimumab dose de-escalation was associated with a complete disappearance of adverse events and this after a median (IQR) of 4.4 (2.9-8.6) months. In more detail, 8 out of 16 patients with skin manifestations had a complete resolution (2 out of 4 with psoriasiform lesions), 3 out of 6 patients with arthralgia (0 out of 1 with a lupus like phenomenon), and 5 out of 7 patients with frequent infectious symptoms. Of note, the two patients in whom the psoriasiform lesions disappeared after dose de-escalation to adalimumab every 3 weeks, had also received psoriasiform specific interventions, namely clobetasol propionate ointment, minocycline and acitretin in the first one, and calcipotriene and betamethason in the other one. We could not identify any predictor of disappearance of adverse events, including serum levels at T0 or T1.
In the control group, all adalimumab-related adverse events persisted throughout follow-up, which was significantly higher than in the study population (100% vs. 55%, LogRank P < 0.001).
DISCUSSION
In this study, we evaluated the outcome of dose de-escalation from adalimumab 40 mg every other week to adalimumab 40 mg every 3 weeks. We identified 40 patients with CD who received monotherapy adalimumab 40 mg every 3 weeks with serum levels available before and after dose de-escalation. During a median follow-up of 2 years, more than one-third of the patients needed to return to adalimumab 40 mg every other week due to clinical relapse, sub-therapeutic adalimumab serum levels or both. The only independent factor associated with dose escalation-free survival was a CRP level less than 3.5 mg/L at dose de-escalation (P = 0.008). The CRP, C-reactive protein; NS, not significant;95% CI, 95% confidence interval.
same factor was associated independently with clinical relapse free survival, and relapse-related discontinuation free survival. In half of the patients dose de-escalation was associated with a complete disappearance of adverse events. Of note, adalimumab serum levels dropped significantly 4 and 8 months after dose de-escalation. However, it was not possible to define a minimal adalimumab serum level at T0 or T1 to consider or maintain dose de-escalation. When compared with a control group of sex-and age-matched patients with CD, the adalimumab serum levels dropped more significantly in patients who deescalated to adalimumab 40 mg every 3 weeks. However, this obvious observation on the short-term was not accompanied with a significant change in clinical (PRO2) or biochemical (CRP and serum albumin) parameters of disease activity. Nevertheless, adalimumab dose de-escalation was more frequently associated with clinical relapse throughout further follow-up. In contrast, disappearance of adalimumab-related adverse events was only observed in the group among those who de-escalated adalimumab therapy.
The finding that 65% of the patients were able to continue adalimumab therapy at a dose of 40 mg every 3 weeks, shows that dose de-escalation of adalimumab is possible in certain patients. Such an approach will clearly have a positive influence on the constantly increasing health costs linked to biological therapy.
While this is probably the first study on dose de-escalation in patients with CD, similar data are available in rheumatology. Both in patients with rheumatoid arthritis and ankylosing spondylitis the high economic burden of biological therapy has led to clinical trials evaluating the possibility of dose de-escalation. The DRESS study in patients with rheumatoid arthritis, showed that dose deescalation with adalimumab (including an eventual adalimumab discontinuation) was successful in two-thirds of patients. 29, 30 After 18 months, dose reduction showed similar outcomes to usual care with adalimumab 40 mg every other week for flares, functional status, clinically relevant radiological joint damage, and adverse events. 31 Furthermore this strategy was associated with a decrease in health care costs without a decrease in quality of life. 30 Recently, Plasencia et al. reported similar results in 77 patients with rheumatoid arthritis receiving standard anti-TNF therapy and 67 patients undergoing a tapering strategy. 32 However, these data are in contrast with a
French randomised controlled trial, where patients undergoing dose tapering and discontinuation developed a clinical relapse more often (76.6% vs. 46.5%). 33 In contrast to the present study, the available data in rheumatoid arthritis did not include tight drug monitoring, and the evaluated patients mostly received combination therapy with disease-modifying anti-rheumatic drugs such as methotrexate. Also in patients with ankylosing spondylitis, Plasencia et al. reported no significant different outcome in patients who tapered their anti-TNF therapy. 34 In the Czech ATTRA registry, a de-escalation regimen with anti-TNF showed a comparable 1-year evolution in the Bath ankylosing spondylitis disease activity index (BAS-DAI), clinical relapse, CRP, disability index, functional index, quality of life, and development of adverse events. 35 . Of note, the mean difference (95% CI) in cost of anti-TNF drugs was €4214 (€3701-€4707) per year of treatment in favour of a reduced dosing strategy. In none of these two trials serum levels were available. The current retrospective cohort study confirms that CRP is an important factor in the individualised therapy of CD. While an elevated CRP has been shown to be a good predictor of response to adalimumab initiation, 36 early CRP normalisation is associated with sustained clinical response. 20, 37 In a Belgian retrospective multicentre adalimumab cohort study, an elevated CRP was associated with a lower response to dose escalation to adalimumab every week, but was not predictive of subsequent dose de-escalation. 24 The present study confirms that CRP is an important predictive factor to select possible candidates for dose de-escalation, suggesting the need for an objective evaluation of disease remission prior to considering dose de-escalation. Unfortunately, we did not have other objective markers available in this retrospective cohort analysis, such as faecal calprotectin or endoscopic activitiy indices. Another factor associated with dose escalation-free survival, relapse free survival, and relapse-related discontinuation free survival in univariate analysis was a body weight above 52 kg. This is somewhat counterintuitive, since most other studies showed worse responses to fixed dosing with adalimumab in patients with an increased body weight or increased BMI. 6, 38 However, a low body weight may be a marker of a worse clinical condition. Indeed, in our cohort a low body weight was associated with lower serum albumin and higher CRP levels (data not shown). This may also explain why this variable was not picked up in multivariate analysis. Individualised therapy with tight direct monitoring is more important in the treatment of IBD. For IFX, ideal serum levels are probably between 3 and 7 lg/mL, 14 whereas for adalimumab, this is less clear. In this study, adalimumab serum level dropped significantly 4 and 8 months after dose de-escalation, but we could not define a minimal adalimumab serum level to consider or maintain dose de-escalation. Further research with larger cohorts and sequential collection of both clinical data and serum are required.
In half of the patients who experienced adalimumabrelated adverse events at baseline, the adverse events disappeared completely. This finding is in contrast with cross sectional findings showing similar serum levels in patients with and without anti-TNF associated skin lesions. 18, 22, 39 In this study we were also unable to demonstrate this relationship or to define a cut-off. However, this study provides evidence that dose de-escalation decreases the occurrence of adverse events demonstrating that the concentration for triggering the events is individually determined. Furthermore, in rheumatoid arthritis, there was no difference in adverse events between the control group and the group with dose deescalation. 31 However, in our study population only four patients had psoriasiform lesions and only one patient had arthralgia linked to a lupus like phenomenon, adverse events clearly linked to anti-TNF therapy. The two patients in whom the psoriasiform lesions disappeared after adalimumab dose de-escalation concomitantly received psoriasis specific therapy.
The main limitations of this study were its retrospective analysis, the relative small population, the absence of endoscopic evaluation (only 16% of the patients underwent endoscopy or radiological imaging within 6 months prior to dose de-escalation) or other objective markers of disease activity such as faecal calprotectin, and the absence of standardised criteria for clinical disease activity at baseline and moment of clinical relapse. Furthermore, adalimumab serum levels were not always available right before a new administration (at through), but drug exposure is less variable with a subcutaneous formulation and therefore this may not have influenced our results.
Although we included a sex-and age-matched control group, this was not optimal since -as expected -these control patients had lower adalimumab serum levels at baseline and less frequently had adalimumab-related adverse events. Prospective randomised placebo-controlled trials including endoscopic endpoints are necessary to investigate the effects of dose de-escalation. Nevertheless, this study suggests that disease remission should be assessed objectively prior to dose de-escalation, with endoscopy, radiology or examination of CRP, serum albumin and/or faecal calprotectin.
In conclusion, dose de-escalation from adalimumab 40 every other week to every 3 weeks was possible in 65% of patients. Additionally, in half of the patients adverse events disappeared completely after dose de-escalation. This is an important finding, since the use of anti-TNF is associated with high costs and debilitating adverse events. Furthermore, the observation of a better midterm outcome in patients with CRP levels lower than 3.5 mg/L suggests the need for a proper evaluation prior to dose de-escalation. Although therapeutic drug monitoring could help us in daily clinical practice to identify possible candidates for dose de-escalation, we could not define a minimal adalimumab serum level to consider or maintain dose de-escalation.
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